BridgeBio Oncology Therapeutics, Inc. (BBOT)
| Market Cap | 1.01B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -87.50M |
| Shares Out | 86.45M |
| EPS (ttm) | -268.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 122,268 |
| Open | 11.72 |
| Previous Close | 11.82 |
| Day's Range | 11.37 - 11.94 |
| 52-Week Range | 8.70 - 12.50 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 25.00 (+113.68%) |
| Earnings Date | n/a |
About BBOT
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics targeting renin-angiotensin system and phosphoinositide 3-kinase malignancies. The company’s product pipeline includes BBO-8520, a direct inhibitor targeting the on and off states of KRAS that is in Phase I clinical trial to treat patients with KRASG12C mutant non-small cell lung cancer; and BBO-10203, an orally bioavailable small molecule that is in Phase I clinical trial for treatment of patients with HER2+ ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for BBOT stock is "Strong Buy." The 12-month stock price target is $25.0, which is an increase of 113.68% from the latest price.
News
BBOT to Participate in Upcoming September Investor Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignan...
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition
Business combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, completed on August 11, 2025. Closed conc...